Evidence map›Paper›PMID 32254064›Full record

ReviewThe Journal of clinical investigation2020

Deployment of convalescent plasma for the prevention and treatment of COVID-19.

Evan M Bloch, Shmuel Shoham, Arturo Casadevall, Bruce S Sachais, Beth Shaz, Jeffrey L Winters, Camille van Buskirk, Brenda J Grossman, Michael Joyner, Jeffrey P Henderson and 17 more

3 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 464 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
464citing papers in PubMed, 12 pooled it
20.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04381858 phase3completednot on this map

Efficacy and Safety of Convalescent Plasma vs Human Immunoglobulin for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Trial

TypeinterventionalSponsorCentenario Hospital Miguel HidalgoRan2020 to 2020Enrolled196ConditionsCOVID-19 PneumoniaArmsPlasma from COVID-19 convalescent patient, Human immunoglobulin
NCT04432103 phase3terminatednot on this map

Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma

TypeinterventionalSponsorCentro Medico ABCRan2020 to 2021Enrolled6ConditionsCovid-19ArmsAnti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients, Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients
NCT05046652 completednot on this map

Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia: A Case Series

TypeobservationalSponsorMaranatha Christian UniversityRan2020 to 2020Enrolled8ConditionsInfectious DiseaseArmsConvalescent Plasma Therapy
3 · Its place in the literature

Who cites it

464 citing papers in PubMed, 12 syntheses or guidelines pooled it, 860 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  4. Convalescent plasma for people with COVID-19: a living systematic review.The Cochrane database of systematic reviews · 2023
    Pooled it
  5. Hyperimmune immunoglobulin for people with COVID-19.The Cochrane database of systematic reviews · 2023
    Pooled it
  6. Guideline
  7. Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022
    Pooled it
  8. Bioethical perspective of convalescent plasma therapy for COVID-19: A systematic review.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2021
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

404 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 12 institutions in 2 countries.

Evan M BlochDivision of Transfusion Medicine, Department of Pathology.
Shmuel ShohamDepartment of Infectious Diseases, School of Medicine, and.
Arturo CasadevallDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Bruce S SachaisNew York Blood Center Enterprises, New York, New York, USA.
Beth ShazNew York Blood Center Enterprises, New York, New York, USA.
Jeffrey L WintersDivision of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Camille van BuskirkDivision of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Brenda J GrossmanDepartment of Pathology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Michael JoynerDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Jeffrey P HendersonDepartment of Medicine and.
Andrew PekoszDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Bryan LauDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Amy WesolowskiDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Louis KatzMississippi Valley Regional Blood Center, Davenport, Iowa, USA.
Hua ShanDepartment of Pathology, Stanford University School of Medicine, Palo Alto, California, USA.
Paul G AuwaerterDepartment of Infectious Diseases, School of Medicine, and.
David ThomasDepartment of Infectious Diseases, School of Medicine, and.
David J SullivanDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
Nigel PanethDepartment of Epidemiology and Biostatistics and.
Eric GehrieDivision of Transfusion Medicine, Department of Pathology.
Steven SpitalnikDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York-Presbyterian Hospital, New York, New York, USA.
Eldad A HodDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York-Presbyterian Hospital, New York, New York, USA.
Lewis PollackIndependent consultant, Princeton, New Jersey.
Wayne T NicholsonDepartment of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Liise-Anne PirofskiDivision of Infectious Diseases, Albert Einstein College of Medicine and Montefiore Medical Center, New York, New York, USA.
Jeffrey A BaileyDepartment of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.
Aaron Ar TobianDivision of Transfusion Medicine, Department of Pathology.
Johns Hopkins University · USMayo Clinic · USInstitute for Transfusion Medicine · USOffice of Infectious Diseases · USNew York Blood Center · USNewYork–Presbyterian Hospital · USWashington University in St. Louis · USAlbert Einstein College of Medicine · USBrown University · USMichigan State University · USOldham Council · GBStanford University · US

Funding

Synergy of Host Defense Mechanisms in the LungR01HL059842 · NHLBI · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1997 to 2023
$7.4M
Conjugate vaccines for prevention and treatment of cryptococcosis - COVID-19 Revision SupplementR01AI152078 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CASADEVALL, ARTURO · 2020 to 2024
$5.1M
The Malaria Transfusion Risk (MATRix) StudyK23HL151826 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BLOCH, EVAN MARTIN · 2020 to 2024
$882k
A prospective evaluation of chronic B.microti infection in seroreactive blood donR21HL117140 · NHLBI · VITALANT · PI BLOCH, EVAN MARTIN · 2013 to 2014
$452k
NHLBI NIH HHS K23 HL151826NHLBI NIH HHS R01 HL059842NIAID NIH HHS R01 AI152078
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e., "convalescent") plasma refers to plasma that is collected from individuals following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy for conferring immediate immunity to susceptible individuals. There are numerous examples in which convalescent plasma has been used successfully as postexposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East respiratory syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads, and improved survival. Globally, blood centers have robust infrastructure for undertaking collections and constructing inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections, and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs. treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, including evidence of benefit, regulatory considerations, logistical work flow, and proposed clinical trials, as scale-up is brought underway to mobilize this critical resource.

Indexed as

BetacoronavirusAntibodies, ViralBlood DonorsCoronavirus InfectionsCOVID-19COVID-19 SerotherapyHumansImmunization, PassiveInvestigational New Drug ApplicationPandemicsPneumonia, ViralRisk AssessmentSARS-CoV-2United StatesUnited States Food and Drug AdministrationAntibodies, Viral

Identifiers

PMID32254064
PMCPMC7259988
OpenAlexW3014853902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.